Gina Mauro

Articles

Novel drug has potential to ‘become new standard of care’ in advanced, ER-positive breast cancer

December 10, 2021

The study results — which were presented during the 2021 San Antonio Breast Cancer Symposium — indicated that elacestrant, a selective estrogen receptor degrader (SERD), led to a 30% reduction in the risk of disease progression or death compared with standard of care in the study population.